Genentech Inactive 10-Q2006 Q1 Quarterly report

Filed: 2 May 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Good

New words: Abgenix, absence, add, addressing, Alfimeprase, AMG, APIC, Astra, attaining, attributable, attribute, automatically, Bayer, Berlex, beta, BioPharma, broader, budgeting, calculate, calculated, calculation, campaign, Campath, CEO, certiorari, CFO, clearing, comparison, compound, CVP, david, departmental, diffuse, discharge, ditosylate, DLBCL, domestic, dose, ebersman, Eli, Eloxatin, emerging, employment, Exhibit, experimental, exposure, eye, false, fiscal, foreseeable, forma, fractionally, fraudulent, FSP, gain, Genotropin, GlaxoSmithKline, grand, grew, healthcare, Humatrope, hypertonic, illegal, inception, incorrect, individual, induce, inexpensive, inflow, insight, internationally, intervention, john, Johnson, kenalog, Kineret, knowingly, lapatinib, Laser, leasehold, Letter, leukotriene, levinson, liable, Lilly, Macugen, malate, mCRC, merged, moderately, modification, molecular, myeloma, neovascular, Nexavar, nonvested, Nordisk, Norditropin, notably, Novo, Nuvelo, Onyx, Orencia, panitumumab, passed, PDL, peer, pertaining, Pfizer, photocoagulation, point, pool, precisely, prohibit, prompt, promulgated, qui, RA, RCC, reaction, rebate, referral, remuneration, requisite, retaliatory, retiree, retirement, retroactive, retroactively, Saizen, saleable, saline, seal, simplified, slight, solicit, sorafenib, stable, statutory, steroid, stromal, subsidiary, sunitinib, Sutent, tam, Telcyta, Telik, Teva, thereunto, TNF, transformed, Tykerb, typically, unanticipated, Unaudited, undersigned, undertaken, unexercised, unnecessary, unsealed, Visudyne, whiting, wholly, willingly, Xeloda, Xyotax, Zactima, Zeneca

Removed: absorbed, acceleration, achievement, acknowledging, adding, agency, aim, amend, amortized, angiogenic, arising, assured, beneficiary, biological, biotech, carboplatin, Chiron, Citizen, classified, collaborator, collectibility, commitment, compelling, concluding, Concurrently, consideration, consolidation, Corporation, criteria, deliver, delivered, delivery, denominator, designing, Detail, determinable, developmental, discontinue, dismissed, element, eliminate, endpoint, entirety, entity, estimating, evaluating, evidence, exceeded, excellent, exclusively, exist, failed, FIN, foregoing, fundamental, guaranteed, high, ImClone, immune, impacted, impacting, initiated, interesting, interference, Interpretation, Iressa, leadership, leasing, ledger, life, loan, Lonza, maintenance, manage, marketplace, meeting, met, molecule, move, narrower, nominating, noncontrolling, Nonrefundable, occurring, opportunity, parking, participated, payable, persuasive, preliminary, prepaid, primary, procurement, proforma, Protecting, prove, publicly, rapid, ratably, reallege, receivable, recent, redeclared, referenced, reliable, rent, repair, repay, requested, restructured, restructuring, revision, scheduled, science, separate, size, split, Stakeholder, steadily, substantive, sufficiently, survival, sustainable, synthetic, Taxol, terminated, title, transferable, undelivered, understand, university, validity, variable, warehouse, wide, workshop, XOMA

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Genentech similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATIONS OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Arthur D. Levinson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Genentech, Inc. on Form 10-Q for the quarter ended March 31, 2006 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report of Genentech, Inc. on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Genentech, Inc.

	By:	/s/ ARTHUR D. LEVINSON
	Name: Title: Date:	Arthur D. Levinson, Ph.D. Chief Executive Officer May 1, 2006

I, David A. Ebersman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Genentech, Inc. on Form 10-Q for the quarter ended March 31, 2006 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report of Genentech, Inc. on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Genentech, Inc.

	By:	/s/ DAVID A. EBERSMAN
	Name: Title: Date:	David A. Ebersman Executive Vice President and Chief Financial Officer May 1, 2006